Whatever the final outcome of pharma’s legal fight over HHS’ price transparency rule for DTC TV, the broader challenge of providing transparency to customers who are demanding it is not going away.
A federal judge struck down a new rule that would have forced pharma companies to include wholesale prices of drugs in TV ads.
U.S. drugmakers filed a lawsuit challenging a new government regulation that would require them to disclose the list price of prescription drugs in direct-to-consumer television advertisements.
HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.
We are on the verge of a medical renaissance, a period of accelerated progress in the treatment and management of rare diseases. This reawakening also brings with it challenges that we must grapple with.
Thanks to a finalized rule requiring price disclosure in DTC advertisements (this is assuming that successful legal challenges do not emerge), what will the impact be and how can the requirement be accommodated while minimizing any confusion that may result?
Stacey Deziel joined Solve(d), FCB Health Network’s data science, marketing analytics and media offering. Benjamin Assor joined Solve(d) as director, media activation.
The Trump administration will require drugmakers to disclose the list price of prescription drugs in DTC TV advertisements, part of the government’s efforts to lower costs for U.S. consumers.
The healthcare ad industry continues to thrive and adapt to the new demands for relevance and creativity.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
